Key Takeaways
- CSE-listed biotech companies have raised $420M combined in 2026, the highest on record for the exchange.
- Three companies NervGen Pharma, Sophiris Bio successor, and Avicanna have active Phase 2 programs.
- CSE biotech market caps are typically $20–150M, making them high-risk but high-leverage plays.
- Due diligence is critical: CSE listings have lower disclosure requirements than TSX-V or major exchanges.
The Canadian Securities Exchange has become a significant listing venue for early-stage biotech companies that need access to public capital markets before they meet the listing requirements of the TSX Venture Exchange or the major US exchanges. With lower listing costs and faster approval timelines, the CSE has attracted a growing cohort of Phase 1 and Phase 2 biotechs some of which are pursuing genuinely innovative science.
Three to Watch
1. NervGen Pharma (NGEN.CSE)
NervGen is developing NVG-291, a small molecule activator of protein tyrosine phosphatase sigma (PTPσ) a target that has shown the ability to promote neural regeneration in spinal cord injury animal models. The company initiated a Phase 2 trial in chronic spinal cord injury in early 2026, enrolling 60 patients across Canadian and US sites. Interim data is expected in Q1 2027. Market cap: approximately $85M.
2. Avicanna (AVCN.CSE)
Avicanna develops pharmaceutical-grade cannabinoid products for specific medical conditions. Its RHO Phyto topical line holds medical device approvals in Canada and is in Phase 2 for neuropathic pain. The company also has early-stage research in oncology-related pain management. Revenue-generating but pre-profitability. Market cap: approximately $38M.
3. Greenfield Acquisition Corp → Biopath Labs
A recently completed reverse merger has created a public vehicle for Biopath Labs, a Montreal-based company developing AI-guided liquid biopsy diagnostics for early cancer detection. Phase 2 validation studies are underway with three major Quebec hospital networks. Market cap post-merger: approximately $62M.